Mahon Paul A exercised Options for 8,300 United Therapeutics shares at $146.03 each, then sold 8,300 shares across 11 transactions priced from $478.93 to $490.88. His directly held shares fell to 45,172 after the sales, while his derivative securities holdings stood at 55,840, giving investors updated ownership figures.

Key Highlights

  • Mahon Paul A exercised options for 8,300 United Therapeutics shares at $146.03 per share on 3 September 2026.
  • He sold 8,300 United Therapeutics shares across 11 transactions at prices ranging from $478.93 to $490.88 per share.
  • Following the transactions, he owned 45,172 United Therapeutics shares and 55,840 derivative securities.

Mahon Paul A, executive vice president and general counsel of United Therapeutics (NASDAQ: UTHR) Corp, exercised options for 8,300 shares at $146.03 per share on 3 September 2026. He then sold the same number of United Therapeutics shares in 11 transactions, with sale prices ranging from $478.93 to $490.88 per share.

United Therapeutics Share Transactions The

option exercise left Mahon with 53,472 United Therapeutics shares before the subsequent sales. The transactions carried SEC code M for the exercise and SEC code S for the sales. After completing the sales, Mahon held 45,172 United Therapeutics shares. The exercise also involved 8,300 derivative securities. Mahon’s derivative securities holdings stood at 55,840 after that transaction.

Updated Direct

and Derivative Holdings The transactions changed the reported balance of Mahon’s United Therapeutics shares from 53,472 after the exercise to 45,172 after the sales. The sales were reported across 11 separate transactions. The filing reports separate ownership figures for United Therapeutics shares and derivative securities. Mahon held 55,840 derivative securities after exercising the options.